On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not as good as continuous hormone therapy with regard to a man’s longevity!

After having thought about the startling conclusions of the phase III study I wrote an additional post about my personal decision to continue current plans to remain on intermittent hormone therapy.

My Current Personal Take on Intermittent Hormone The